Adaptive pathways and PRIME: A true acceleration of drug development and approval?

The European Medicines Agency (EMA) has launched two initiatives - Adaptive Pathways and PRIME (PRIorityMEdicines) - to improve timely access for patients to new and promising medicines. How do this initiatives work and will they truly accelerate drug development and approval or should they rather be perceived as old wine in new tubes?

<link https: static1.squarespace.com static t pm317_158-163-seimetz.pdf internal link in current>Read more from Dr. Diane Seimetz, one of the lecturers in the GBS Pharma MBA Strategic Management & Corporate Development module.

Dr. Diane Seimetz holds a degree in pharmaceutical sciences and completed her PhD at the German Cancer Research Center and the Johns Hopkins University in Baltimore (USA). She also holds a Master’s Degree in Drug Regulatory Affairs and is an experienced drug development and regulatory expert with proven track record bringing first in class products from idea to approval. Dr. Seimetz has over 19 years of global drug development, regulatory affairs and partnering experience in the pharmaceutical industry.

Back